A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  American Journal of Tropical Medicine and Hygiene

• Publication date

  2001-11-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.4269/AJTMH.2001.65.414PMID 11716092
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• From the Centers for Disease Control and Prevention. Public health dispatch: outbreak of poliomyelitis--Dominican Republic and Haiti, 2000.

  2001cited by this paper
• Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

  2001cited by this paper
• Invited commentary: Dengue lessons from Cuba.

  2000cited by this paper
• Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.

  2000cited by this paper
• Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates

  2000cited by this paper
• The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland.

  2000cited by this paper
• Attenuation Markers of a Candidate Dengue Type 2 Vaccine Virus, Strain 16681 (PDK-53), Are Defined by Mutations in the 5′ Noncoding Region and Nonstructural Proteins 1 and 3

  2000cited by this paper
• Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996–1997 dengue‐2 outbreak in French Polynesia

  2000cited by this paper
• Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine

  2000cited by this paper
• Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccines dengue-1 PDK13, dengue-3 PGMK30F3, and dengue-4 PDK48 after oral infection in Aedes aegypti.

  1999cited by this paper
• Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.

  1999cited by this paper
• Impact of dengue/dengue hemorrhagic fever on the developing world.

  1999cited by this paper
• Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties

  1999cited by this paper
• Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4.

  1998cited by this paper
• Effect of size and geographic origin of Aedes aegypti on oral infection with dengue-2 virus.

  1998cited by this paper
• Dengue and Dengue Hemorrhagic Fever

  1998cited by this paper
• Quantitative genetics of vector competence for dengue-2 virus in Aedes aegypti.

  1998cited by this paper
• Impact of dengue virus infection and its control.

  1997cited by this paper
• Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys

  1996cited by this paper
• Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice

  1995cited by this paper
• Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti.

  1994cited by this paper
• Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus.

  1991cited by this paper
• Construction of intertypic chimeric dengue viruses by substitution of structural protein genes.

  1991cited by this paper
• Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: a possible marker of human attenuation.

  1991cited by this paper
• Comparative susceptibility of mosquito species and strains to oral and parenteral infection with dengue and Japanese encephalitis viruses.

  1985cited by this paper
• Quantity of dengue virus required to infect rhesus monkeys.

  1985cited by this paper
• Evaluation of Toxorhynchites splendens (Diptera: Culicidae) as a bioassay host for dengue viruses.

  1982cited by this paper
• Dengue-2 vaccine: infection of Aedes aegypti mosquitoes by feeding on viremic recipients.

  1982cited by this paper
• The use of mosquitoes to detect and propagate dengue viruses.

  1974cited by this paper
• Studies on the Feeding Response of Mosquitoes to Nutritive Solutions in a New Membrane Feeder.

  1964cited by this paper
• Research on dengue during World War II.

  1952cited by this paper
• A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS

  1938cited by this paper

• From promise to pitfalls: immunological lessons from dengue vaccines and their implications.

  2026cites this paper
• Diagnostic Techniques for Dengue Virus.

  2025cites this paper
• Dengue Vaccines.

  2025cites this paper
• Knowledge-based mitigation of the environmental risk of Orthoflavivirus live-attenuated vaccines by targeting viral encoded determinants for the mosquito attenuated phenotype.

  2025cites this paper
• Evaluation of DENV‐Mediated Potential of Aedes albopictus (KDCA Strain) Through Comparative Experiments With Aedes aegypti

  2025cites this paper
• Subgenomic flavivirus RNA as key target for live-attenuated vaccine development

  2024cites this paper
• Current status of the development of dengue vaccines

  2024cites this paper
• Vacunas contra el dengue

  2024cites this paper
• The dengue virus 4 component of NIAID’s tetravalent TV003 vaccine drives its innate immune signature

  2022cites this paper
• Dengue Vaccines: An Update

  2022cites this paper
• Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines

  2022cites this paper
• Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.

  2020cites this paper
• A Review on Dengue Vaccine Development

  2020cites this paper
• Dengue Vaccines: An Update

  2020cites this paper
• Anti-dengue Vaccines: From Development to Clinical Trials

  2020cites this paper
• The Interplay between Dengue Virus and the Human Innate Immune System: A Game of Hide and Seek

  2019cites this paper
• RNA Structure Duplication in the Dengue Virus 3′ UTR: Redundancy or Host Specificity?

  2019cites this paper
• Decreased accumulation of subgenomic RNA in human cells infected with vaccine candidate DEN4Δ30 increases viral susceptibility to type I interferon.

  2018cites this paper
• Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus.

  2017cites this paper
• The 5′ and 3′ Untranslated Regions of the Flaviviral Genome

  2017cites this paper
• Rise and fall of vector infectivity during sequential strain displacements by mosquito‐borne dengue virus

  2016cites this paper
• Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

  2015cites this paper
• Dengue vaccines: challenges, development, current status and prospects.

  2015cites this paper
• Dual miRNA Targeting Restricts Host Range and Attenuates Neurovirulence of Flaviviruses

  2015cites this paper
• Functions of the 3' and 5' genome RNA regions of members of the genus Flavivirus.

  2015cites this paper
• Tackling dengue fever: Current status and challenges

  2015cites this paper
• The tortoise or the hare? Impacts of within-host dynamics on transmission success of arthropod-borne viruses

  2015cites this paper
• Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine.

  2015cites this paper
• Flavivirus-Mosquito Interactions

  2014cites this paper
• Vaccine Development as a Means to Control Dengue Virus Pathogenesis: Do We Know Enough?

  2014cites this paper
• Dengue virus vaccine development.

  2014cites this paper
• Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.

  2013cites this paper
• Replacing a Native Wolbachia with a Novel Strain Results in an Increase in Endosymbiont Load and Resistance to Dengue Virus in a Mosquito Vector

  2013cites this paper
• Replacement of conserved or variable sequences of the mosquito-borne dengue virus 3' UTR with homologous sequences from Modoc virus does not change infectivity for mosquitoes.

  2013cites this paper
• Short Communication Replacement of conserved or variable sequences of the mosquito-borne dengue virus 39 UTR with homologous sequences from Modoc virus does not change infectivity for mosquitoes

  2013cites this paper
• Chikungunya Virus 3′ Untranslated Region: Adaptation to Mosquitoes and a Population Bottleneck as Major Evolutionary Forces

  2013cites this paper
• Advances in the development of vaccines for dengue fever

  2012cites this paper
• Wolbachia Induces Density-Dependent Inhibition to Dengue Virus in Mosquito Cells

  2012cites this paper
• The entomopathogenic fungus Beauveria bassiana activate toll and JAK-STAT pathway-controlled effector genes and anti-dengue activity in Aedes aegypti.

  2012cites this paper
• Core protein-mediated 5′–3′ annealing of the West Nile virus genomic RNA in vitro

  2012cites this paper
• Functions and requirements of conserved RNA structures in the 3’ untranslated region of Flaviviruses

  2011cites this paper
• Wolbachia induces reactive oxygen species (ROS)-dependent activation of the Toll pathway to control dengue virus in the mosquito Aedes aegypti

  2011cites this paper
• Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

  2011influential citation
• Vaccination and antiviral treatment of neglected diseases caused by flaviviral infections.

  2011cites this paper
• Immune response to dengue virus and prospects for a vaccine.

  2011cites this paper
• Chimeric Tick-Borne Encephalitis/Dengue Virus Is Attenuated in Ixodes scapularis Ticks and Aedes aegypti Mosquitoes

  2011cites this paper
• Replacement of the 3' untranslated variable region of mosquito-borne dengue virus with that of tick-borne Langat virus does not alter vector specificity.

  2011cites this paper
• Recombinant, Chimeric, Live, Attenuated Vaccines Against Flaviviruses and Alphaviruses

  2011cites this paper
• Short Communication Replacement of the 39 untranslated variable region of mosquito-borne dengue virus with that of tick- borne Langat virus does not alter vector specificity

  2011cites this paper
• La dengue : un vaccin à l'horizon 2015

  2011cites this paper
• Replication of the Primary Dog Kidney-53 Dengue 2 Virus Vaccine Candidate in Aedes aegypti Is Modulated by a Mutation in the 5′ Untranslated Region and Amino Acid Substitutions in Nonstructural Proteins 1 and 3

  2011cites this paper
• The Toll immune signaling pathway control conserved anti-dengue defenses across diverse Ae. aegypti strains and against multiple dengue virus serotypes.

  2010cites this paper
• The Endosymbiotic Bacterium Wolbachia Induces Resistance to Dengue Virus in Aedes aegypti

  2010cites this paper
• Targeted mutagenesis as a rational approach to dengue virus vaccine development.

  2010cites this paper
• RNA interference modulates replication of dengue virus in Drosophila melanogaster cells

  2010cites this paper
• An evolutionary conserved function of the JAK-STAT pathway in anti-dengue defense

  2009cites this paper
• Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4D30 -4995 in Healthy Adult Volunteers

  2009cites this paper
• Dengue Virus Host Factors

  2009cites this paper
• Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 D 30 -4995 in Healthy Adult Volunteers

  2009cites this paper
• Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.

  2009cites this paper
• The Aedes aegypti Toll Pathway Controls Dengue Virus Infection

  2008cites this paper
• Asymmetric competitive suppression between strains of dengue virus

  2008cites this paper
• Density-Dependent Competitive Suppression of Sylvatic Dengue Virus by Endemic Dengue Virus in Cultured Mosquito Cells

  2008cites this paper
• Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.

  2008influential citation
• Superior infectivity for mosquito vectors contributes to competitive displacement among strains of dengue virus

  2008cites this paper
• Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.

  2008cites this paper
• Dengue vaccines approach the finish line.

  2007cites this paper
• Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Δ30 with those of DEN1

  2007cites this paper
• Prospects for a dengue virus vaccine

  2007cites this paper
• Development of novel vaccines for the concurrent immunisation against multiple dengue virus serotypes

  2006cites this paper
• rDEN2/4Δ30(ME), a Live Attenuated Chimeric Dengue Serotype 2 Vaccine, is Safe and Highly Immunogenic in Healthy Dengue-Naïve Adults

  2006cites this paper
• Manipulation of the yellow fever virus non-structural genes 2A and 4B and the 3'non-coding region to evaluate genetic determinants of viral dissemination from the Aedes aegypti midgut.

  2006cites this paper
• Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand.

  2006cites this paper
• Development of a Live Attenuated Dengue Virus Vaccine Using Reverse Genetics

  2006influential citation
• The Live Attenuated Dengue Serotype 1 Vaccine rDEN1Δ30 is Safe and Highly Immunogenic in Healthy Adult Volunteers

  2006cites this paper
• rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers

  2005cites this paper
• Dengue and dengue vaccines.

  2005cites this paper
• rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.

  2005cites this paper
• Infectivity of West Nile/Dengue Chimeric Viruses for West Nile and Dengue Mosquito Vectors

  2005cites this paper
• Role of RNA structures present at the 3'UTR of dengue virus on translation, RNA synthesis, and viral replication.

  2005cites this paper
• Size Heterogeneity in the 3′ Noncoding Region of South American Isolates of Yellow Fever Virus

  2005cites this paper
• Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus

  2005cites this paper
• Yellow Fever Virus Region of South American Isolates of Noncoding ′ Size Heterogeneity in the 3

  2004cites this paper
• Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2

  2004cites this paper
• Desarrollo de vacunas frente a las infecciones por dengue

  2004cites this paper
• Recent advancement in flavivirus vaccine development

  2004cites this paper
• Genetically modified, live attenuated dengue virus type 3 vaccine candidates.

  2004cites this paper
• Salivary Gland of Toxorhynchites splendens Wiedemann (Diptera: Culicidae): Ultrastructural Morphology and Electrophoretic Protein Profiles

  2004cites this paper
• Dengue vaccine: priorities and progress

  2004cites this paper
• Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.

  2003cites this paper
• Vaccines for the prevention of neglected diseases--dengue fever.

  2003cites this paper
• Vacunas contra el virus dengue: desarrollo histórico

  2003cites this paper
• A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4.

  2003influential citation
• Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

  2003cites this paper
• American Genotype Structures Decrease Dengue Virus Output from Human Monocytes and Dendritic Cells

  2003cites this paper
• A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3′ Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys

  2003cites this paper
• Traditional and novel approaches to flavivirus vaccines.

  2003cites this paper
• Tetravalente dengue-vakzine mit einer blichen 30 nucleotid-deletion in 3'-utr von dengue-typen 1,2,3 und 4, oder antigene chimäre dengue-viren 1,2,3 und 4

  2003cites this paper
• Rekombinanter Dengue Virus mit einer allgemeinen 30-Nukleotid Deletion im 3'-UTR der Dengue-Virus Typen 3 oder 4

  2003cites this paper
• Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.

  2003influential citation